Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide.
HBsAg loss is associated with functional remission and improved long‐term outcome, and is …

Chronic hepatitis B (CHB) remains a global healthcare burden. Although the recent
developments in the field have led to a reduction in incidence, the morbidity and mortality …

In spite of a decrease in the prevalence and incidence seen in recent years, chronic
hepatitis B (CHB) still remains a major healthcare challenge, prevalent mostly in developing …

Hepatitis B virus (HBV) infection is a public health threat worldwide, and there is no direct
treatment yet available. In the event of infection, patients may present liver cirrhosis and …

Viral hepatitis has long been underrated as a danger to global health. The UN only recently
called for worldwide action to tackle viral hepatitis and lessen the disease burden in its …

Chronic hepatitis B (CHB) is associated with significant morbidity and mortality, due to the
adverse sequelae of cirrhosis and hepatocellular carcinoma (HCC). To date, antiviral …

BACKGROUND Diffusion-weighted magnetic resonance imaging has shown promise in the
detection and quantification of hepatic fibrosis. In addition, the liver has numerous …

The goals of antiviral therapy in patients with chronic hepatitis B (CHB) are to prevent
disease progression and reduce the risk of hepatocellular carcinoma (HCC). 1–3 Treatment …

Hepatitis B virus (HBV) infection is estimated to affect 292 million people worldwide, 90% of
them are unaware of their HBV status. The Determine HBsAg 2 (Alere Medical Co, Ltd Chiba …